PDF(Pubmed)
Abstract：
UNASSIGNED: This literature review explores the role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and neutrophil-lymphocyte-to-platelet ratio (NLPR) biomarkers, as potential indicators for predicting bacteremia and sepsis in patients with cancer.
UNASSIGNED: Tracing the evolution of interest in this area since 2001, the aim of this review was to report a comprehensive overview of current knowledge and gaps, particularly in patients undergoing immunosuppression.
UNASSIGNED: The literature research indicates the potential of NLR, PLR, and other biomarkers in diagnosing and predicting sepsis, with some studies emphasizing their value in mortality prediction. A specific focus on bacteremia shows the effectiveness of NLR and PLR as early indicators and prognostic tools, though mostly in noncancer patient populations. While NLR and PLR are promising in general cancer patient populations, the review addresses the challenges in applying these biomarkers to patients with neutropenic and lymphopenic cancer. The NLPR could be considered a significant biomarker for inflammation and mortality risk in various medical conditions, yet its diagnostic accuracy in patients with immunosuppressed cancer is not extensively validated.
UNASSIGNED: This review offers a snapshot of the current research on biomarkers in patients with immunocompromised cancer in the sepsis and bacteremia area. More focused research on their application is necessary. This gap underscores an opportunity for future studies to enhance diagnostic and prognostic capabilities in this high-risk group.
UNASSIGNED: Tracing the evolution of interest in this area since 2001, the aim of this review was to report a comprehensive overview of current knowledge and gaps, particularly in patients undergoing immunosuppression.
UNASSIGNED: The literature research indicates the potential of NLR, PLR, and other biomarkers in diagnosing and predicting sepsis, with some studies emphasizing their value in mortality prediction. A specific focus on bacteremia shows the effectiveness of NLR and PLR as early indicators and prognostic tools, though mostly in noncancer patient populations. While NLR and PLR are promising in general cancer patient populations, the review addresses the challenges in applying these biomarkers to patients with neutropenic and lymphopenic cancer. The NLPR could be considered a significant biomarker for inflammation and mortality risk in various medical conditions, yet its diagnostic accuracy in patients with immunosuppressed cancer is not extensively validated.
UNASSIGNED: This review offers a snapshot of the current research on biomarkers in patients with immunocompromised cancer in the sepsis and bacteremia area. More focused research on their application is necessary. This gap underscores an opportunity for future studies to enhance diagnostic and prognostic capabilities in this high-risk group.
摘要：
■这篇文献综述探讨了中性粒细胞与淋巴细胞比率(NLR)的作用，血小板与淋巴细胞比率（PLR），和中性粒细胞-淋巴细胞与血小板比率（NLPR）生物标志物，作为预测癌症患者菌血症和败血症的潜在指标。
■追踪自2001年以来对该领域的兴趣演变，本次审查的目的是报告对当前知识和差距的全面概述，特别是在接受免疫抑制的患者中。
■文献研究表明了NLR的潜力，PLR,和其他诊断和预测脓毒症的生物标志物，一些研究强调了它们在死亡率预测中的价值。特别关注菌血症表明NLR和PLR作为早期指标和预后工具的有效性。虽然主要在非癌症患者人群中。虽然NLR和PLR在一般癌症患者人群中很有希望，该综述解决了将这些生物标志物应用于中性粒细胞减少和淋巴细胞减少癌患者的挑战.NLPR可以被认为是各种医疗条件下炎症和死亡风险的重要生物标志物。然而，其在免疫抑制癌症患者中的诊断准确性尚未得到广泛验证。
■这篇综述提供了当前在脓毒症和菌血症领域免疫功能低下的癌症患者中生物标志物研究的快照。有必要对其应用进行更集中的研究。这一差距凸显了未来研究提高这一高危人群诊断和预后能力的机会。
■追踪自2001年以来对该领域的兴趣演变，本次审查的目的是报告对当前知识和差距的全面概述，特别是在接受免疫抑制的患者中。
■文献研究表明了NLR的潜力，PLR,和其他诊断和预测脓毒症的生物标志物，一些研究强调了它们在死亡率预测中的价值。特别关注菌血症表明NLR和PLR作为早期指标和预后工具的有效性。虽然主要在非癌症患者人群中。虽然NLR和PLR在一般癌症患者人群中很有希望，该综述解决了将这些生物标志物应用于中性粒细胞减少和淋巴细胞减少癌患者的挑战.NLPR可以被认为是各种医疗条件下炎症和死亡风险的重要生物标志物。然而，其在免疫抑制癌症患者中的诊断准确性尚未得到广泛验证。
■这篇综述提供了当前在脓毒症和菌血症领域免疫功能低下的癌症患者中生物标志物研究的快照。有必要对其应用进行更集中的研究。这一差距凸显了未来研究提高这一高危人群诊断和预后能力的机会。
